Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Autoimmune Disorders

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

TIM3 Signaling in Effector T Cells Acts as an Immunometabolic Switch in the Purine Degradation Pathway to Suppress Intestinal Inflammation.

Gastroenterology·2026

Same author

SATB1 is a targetable modulator of JAK-STAT signaling and cytokines in human Treg and Tconv cells.

EMBO reports·2026

Same author

Author Correction: Regulatory T cells in the mouse hypothalamus control immune activation and ameliorate metabolic impairments in high-calorie environments.

Nature communications·2026

Same author

Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial.

Inflammatory bowel diseases·2026

Same author

Early Gut-Vascular Barrier Breakdown Precedes Colitis Onset in Murine Models.

Cellular and molecular gastroenterology and hepatology·2026

Same author

SATB1 is a targetable modulator of JAK-STAT signaling and cytokines in human Treg and Tconv cells.

bioRxiv : the preprint server for biology·2026

Search research articles

Related Experiment Video

Updated: May 14, 2026

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Immunotherapy in autoimmune type 1 diabetes.

Benno Weigmann¹, Randi K Franke, Carolin Daniel

¹Research Campus of the Friedrich-Alexander University Erlangen-Nuernberg, Medical Clinic I, 91052 Erlangen, Germany.

The Review of Diabetic Studies : RDS

|February 14, 2013

Summary

Type 1 diabetes (T1D) is a growing autoimmune disease. Immunotherapies, especially those involving Foxp3+ regulatory T (Treg) cells, show promise for preventing and treating T1D by restoring self-tolerance.

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

Related Experiment Videos

Last Updated: May 14, 2026

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

Area of Science:

Immunology
Endocrinology
Autoimmunity

Background:

Type 1 diabetes (T1D) is a chronic autoimmune condition characterized by pancreatic beta-cell destruction and hyperglycemia.
The global incidence and prevalence of T1D are increasing, necessitating novel immunotherapeutic interventions.
Restoring immunological self-tolerance is crucial for preventing and treating T1D.

Purpose of the Study:

To review current immunotherapeutic strategies for autoimmune Type 1 diabetes.
To discuss the role of Foxp3+ regulatory T (Treg) cells in maintaining self-tolerance.
To highlight emerging clinical trials and antigen-specific Treg cell therapies for T1D.

Main Methods:

Review of existing literature on T1D immunotherapies.
Analysis of studies involving general immunosuppressive agents (e.g., cyclosporin A).
Examination of research on Foxp3+ Treg cell generation and function.

Main Results:

Early immunointervention studies utilized broad immunosuppression with limited success.
Foxp3+ Treg cells are key regulators of self-tolerance.
Emerging therapies focus on antigen-specific Treg cell induction for targeted autoimmunity treatment.

Conclusions:

Immunotherapeutic approaches are vital for managing the rising burden of Type 1 diabetes.
Harnessing Foxp3+ Treg cells offers a promising avenue for safe and specific T1D treatment.
Antigen-specific Treg cell therapies represent a significant advancement in autoimmune disease management.